Carotid artery intima-media thickness in psoriatic patients and its relation to severity and duration of the disease
DOI:
https://doi.org/10.66344/jpad.31.3.2021.1640Keywords:
Key Words, Carotid Artery Intima-Media Thickness, psoriasis, severity, duration of the diseaseAbstract
Objective The study was conducted to find out the relation between the severity and duration of psoriasis with carotid artery intima-media thickness in psoriatic patients.  Methods This descriptive type of cross-sectional study was conducted during the period of April 2016 to August 2017. Fifty psoriatic patients were enrolled through purposive sampling. History was taken, physical examination and necessary laboratory tests were done for each of the participants. Disease severity of each and every patient was measured by Psoriasis Area Severity Index (PASI). High-resolution B-mode ultrasonography with a linear array transducer and ultrasound frequencies 5–15 MHz was used to measure CIMT. All the data were recorded using predesigned questionnaire. Continuous data were expressed as the mean ± standard deviation (SD). Pearson correlation coefficient test was used to correlate between mean carotid intima-media thickness with continuous variable.  Results The mean age of the patients was 33.0±10.5 years and 74.0% patients were male. The mean duration of disease was 44.1±54.4 months, onset of disease was at the age of 28.4±10.6 years, the PASI was 14.4±10.1 and overall 10.0% of the patients had ≥0.9 mm (abnormal) CIMT. There was significant association between mean CIMT values and duration of disease (r= +0.587, p<0.001) and also significant positive correlation between mean CIMT with age (r= +0.460, p<0.001) but insignificant positive correlation between mean CIMT and PASI score (r = +0.045, p=0.756).  Conclusion Psoriatic patients had a relationship between increasing mean carotid artery intima-media thickness and duration of disease that may predict a higher risk of cardioÂvascular diseases. So, all psoriatic patients should be advised to avoid traditional cardiovascular risk factors to reduce cardiovascular morbidity and mortality. ÂReferences
References
Maria IM, Loring B. Global report on psoriasis. WHO. 2011:1–48.
Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007;370:263–71.
Lowes MA, Bowcock AM, Krueger JG Pathogenesis and therapy of psoriasis. Nature. 2007; 445:866–73.
Takahashi H, Izuka H. Psoriasis and metabolic syndrome. The Journal of dermatology. 2012;39:212–8.
Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. Journal of Dermatological Treatment. 2008;19:5–21.
Tesmer LA. Th17 cells in human disease. Immunology Reviews. 2008;223:87–113.
Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, Gelfand JM. Attributable risk estimate of severe psoriasis on major cardiovascular events. The American journal of medicine. 2011;124:775–e1.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. Jama. 2006;296:1735–41.
Balta I, Belta S, Demirkol S, Celik T, Ekiz O, Cakar M, Sarlak H, Ozoguz P, Iyisoy A. Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris. Angiology. 2014;65:74–8.
Spah F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. British journal of Dermatology. 2008;159:10–7.
Nofal A, Al-Makhzangly I, Attwa E, Nassar A, Abdalmoati A. Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. Journal of the European Academy of Dermatology and Venereology. 2009;23:803–6.
Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. International journal of clinical practice. 2008;62(8):1246–54.
Vandenbroucke JP, von Elme E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. STROBE Initiative. PLoS Med. 2007;4:e297.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of dermatological research. 2011;303:1–10.
Bauer M, Caviezel S, Teynor A, Erbel R, Mahabadi AA, Schmidt-Trucksäss A. Carotid intima-media thickness as a biomarker of subclinical atherosclerosis. Swiss medical weekly. 2012;142:w13705
Shahidi-Daras M, Haghighatkhah HR, Abdollhimajid F, Younespour S, Kia MP and Zargari O. Correlation between vascular endothelial growth factor and subclinical atherosclerosis in patients with psoriasis. International journal of dermatology. 2015;55:2–9.
Enany BEl, Zohiery AK, Elhilaly R, Badr T. Carotid intima-media thickness and serum leptin in psoriasis. Herz. 2012;37:527–33.
S Elâ€Mongy, H Fathy, A Abdelaziz, E Omran, S George, N Neseem N Elâ€Nour. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. Journal of the European Academy of Dermatology and Venereology. 2010; 24:661–6.
Biswas AK, Bala S, Sen S, Bandyopadhyay A, Chakraborty S, Choudhury S, Jain A, Majumdar B, Chatterjee G. Psoriasis and subclinical atherosclerosis: A significant association. Journal of Pakistan Association of Dermatologists. 2015 Jan 1;25:4-8.
Asha K, Sharma S, Singal A, Aggarwal A. Association of carotid intima-media thickness with leptin and apolipoprotien ratio imminent predictors of subclinical atherosclerosis in psoriatic patients. ActaMedica (Hradec Kralove). 2014;57:21–7.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.